Acute Coronary Syndrome, Angina Pectoris, Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia
Conditions
Keywords
acute coronary syndrome, coronary disease, coronary artery disease
Brief summary
The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.
Interventions
DRUGTicagrelor
180mg loading and 90mg bid
DRUGClopidogrel
600mg loading and 75mg qd
Sponsors
CardioVascular Research Foundation, Korea
Seung-Jung Park
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 and more * Index event of non-ST or ST segment elevation ACS * Provision of signed informed consent
Exclusion criteria
* Hypersensitivity to aspirin or ticagrelor * Oral anticoagulation therapy that cannot be stopped * Treated with thrombolysis within 24hrs * Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor * Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers * Any life-threatening condition with life expectancy less than 6months * Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study * High risk due to malignant hypertension * The conditions associated with increased risk of bradycardiac events * Subjects with severe liver disease * Subjects requiring dialysis * Increased bleeding risk * History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days * Thrombocytopenia or leukopenia * Positive pregnancy test or is known to be pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time to first occurrence of any bleeding event | 1year | Safety of Ticagrelor compared to Clopidogrel by measuring the time to first occurrence of any bleeding event(including major, minor bleedings) |
| The time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke | 1year | Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The time to first occurrence of major bleeding event or minor bleeding event | 1year | The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria |
| The time to first occurrence of Bleeding Academic Research Consortium (BARC) bleeding event from type 1 to type 5 | 1year | By Bleeding Academic Research Consortium(BARC) Definition of Bleeding Events |
| The time of first occurrence of discontinuation of study medication from any bleeding event | 1year | — |
| Non serious adverse events | 1year | — |
| Adverse events following discontinuation of study medication | 1year | — |
| Serious adverse events | 1year | — |
| The time to first occurrence of major bleeding event | 1year | by PLAtelet inhibition and patient Outcomes(PLATO) criteria |
| The time to first occurrence of myocardial infarction | 1year | Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of myocardial infarction |
| The time to first occurrence of stroke | 1year | Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of stroke |
| The time to occurrence of composite events | 1year | The time to occurrence of composite events(death from any cause, myocardial infarction, stroke) |
| The time to occurrence of death from any cause | 1year | — |
| Number of patients with net clinical benefit of any total bleeding and any event from the composite of death from vascular causes, Myocardial Infarction and stroke. | 1year | — |
| The time to first occurrence of death from vascular causes | 1year | Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of death from vascular causes |
| The time to first occurrence of minor bleeding event | 1year | by PLAtelet inhibition and patient Outcomes(PLATO) criteria |
Countries
South Korea
Outcome results
None listed